Zachary Marshall-Carter (Zach)

Associate

ニューヨーク + 1.212.326.3448

Zach Marshall-Carter is a litigator with a focus on intellectual property. He represents life sciences, technology, and financial services clients in patent litigation in federal district courts and before the Patent Trial and Appeal Board.

Zach's litigation practice focuses on complex patent disputes for life sciences and technology clients, including Hatch-Waxman and Biologics Price Competition and Innovation Act litigation, as well as matters involving diagnostics and biotechnology platforms. He also litigates patent matters involving software and financial technology.

Zach handles all phases of patent litigation, from developing invalidity and infringement strategy and briefing claim construction to managing complex discovery, working with experts, and preparing for trial.

Zach also maintains an active pro bono practice. He works with Kids in Need of Defense (KIND) and Her Justice to represent clients in immigration and family court matters related to claims for asylum, Special Immigrant Juvenile status, custody, and orders of protection. Zach's pro bono experience includes arguing motions, examining witnesses at hearings, and negotiating settlements. Zach was part of a team of Jones Day attorneys who were recognized with Her Justice's 2025 Legal Team Award.

Prior to attending law school, Zach taught biology as a 2018 Teach For America corps member in Lawrence, Massachusetts. He also actively volunteers to coach, mentor, and judge students in trial advocacy competitions and previously served as the head coach of the University of Massachusetts Lowell mock trial program.

担当案件

  • Organon and Shanghai Henlius resolve 26-patent BPCIA litigation with Amgen over denosumab biosimilarsJones Day represented Organon LLC, Organon & Co. (collectively "Organon"), Shanghai Henlius Biotech, Inc., and Shanghai Henlius Biologics Co., Ltd. (collectively "Shanghai Henlius") in patent litigation under the Biologics Price Competition and Innovation Act (BPCIA) filed in June 2025 by Amgen Inc. and Amgen Manufacturing Limited LLC (collectively "Amgen") in the U.S. District Court for the District of New Jersey.